This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum ...

The Japan axillary hyperhidrosis treatment market is experiencing significant growth, with projections indicating a rise from USD 66.9 million in 2025 to USD 134.1 million by 2035, reflecting a CAGR ...

The India axillary hyperhidrosis treatment market is on a strong growth trajectory, projected to expand at a CAGR of 10.1%, rising from USD 75.2 million in 2025 to USD 196.8 million by 2035. This ...

Some individuals sweat excessively compared to others, to the extent that their clothes become drenched. This excessive ...

This would be Dermata’s second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical ...

This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial ...

Dermata Therapeutics (DRMA) announced the Australian Patent Office has accepted its patent application for its DMT410 program for the treatment ...

Although sweating is a normal physiological reaction, excessive sweating is sometimes explained by a little-known disorder ...